Camporeale A, et al. – In this phase 3, multicenter, randomized, long-term, open-label study, researchers assessed the safety, tolerability, and effectiveness of galcanezumab for up to 12 months of treatment in patients with migraine. Study participants included patients (18 to 65 years of age) with episodic or chronic migraine who were not exposed previously to galcanezumab. Study participants were randomized to receive galcanezumab 120 mg or 240 mg, which was administered subcutaneously once monthly for a year. According to findings, 12 months of treatment with self-administered injections of galcanezumab was safe and related to a decline in the number of monthly migraine headache days. There were no significant differences in doses of galcanezumab in terms of safety and tolerability measures.